Atlas Trials

A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression

Clinical trial NCT05189197 · UNKNOWN

Trial details

NCT number
NCT05189197
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B-cell Lymphoma(DLBCL)
Start date
2022-01-18
Primary completion
2025-01-01
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.